(Q39502346)

12 September 2017

1 reference

title

Acebutolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects (English)

1 reference

12 September 2017

1 reference

1 reference

Singh BN

1

1 reference

12 September 2017

Thoden WR

series ordinal

2

1 reference

12 September 2017

Wahl J

series ordinal

3

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 March 1986

1 reference

12 September 2017

1 reference

12 September 2017

6

1 reference

12 September 2017

2

1 reference

12 September 2017

45-63

1 reference

Pharmacokinetics, Central Nervous System Uptake, and Lipid Solubility of Propranolol, Acebutolol, and Sotalol

12 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Beta-adrenoceptor blocking properties and cardioselectivity of M & B 17,803A

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The selectivity of beta-adrenoceptor antagonists on cardiovascular and bronchodilator responses to isoprenaline in the anaesthetized dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The assessment of -adrenoceptor blocking potency and cardioselectivity in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

A comparison of the bronchoconstrictor and beta-adrenoceptor blocking activity of propranolol and acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Pharmacological properties of diacetolol (M&B 16,942), a major metabolite of acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Mechanisms of antihypertensive action of beta-adrenergic blocking drugs: evidence against potentiation of baroreflexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Central adrenoreceptors and the control of arterial blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The central uptake of beta-adrenoceptor antagonists [proceedings]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

A comparison of the experimental anti-arrhythmic properties of acebutolol (M and B 17,803), propranolol and practolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acebutolol-induced changes in refractoriness and monophastic action potential of the right ventricle of the dog heart in situ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

A study of the relationship between cardiac ?-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acebutolol, metoprolol and propranolol in conscious dogs with chronic heart-block: chronotropic effects and relation between depression of ventricular activity and beta-adrenoceptor blocking potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Effects of acebutolol, practolol and propranolol on the rat heart sarcolemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

-adrenoceptor antagonists and the release of creatine phosphokinase from hypoxic heart muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The effects of propranolol and acebutolol on left ventricular function and coronary haemodynamics in the conscious dog with myocardial ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Effect of M & B 17803A, a new -adrenoceptor blocking agent, on the cardiovascular responses to tilting and to isoprenaline in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Onset and duration of beta-adrenergic receptor blockade following single oral dose acebutolol hydrochloride (Sectral)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acute hemodynamic effects and cardioselectivity of acebutolol, practolol, and propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Cardiac and pulmonary effects of acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

A comparison of four beta-adrenoceptor antagonists in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Electrophysiological effects of acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Electrophysiological properties of intravenous metoprolol in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Clinical electrophysiological effects of atenolol--a new cardioselective beta-blocking agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The electrophysiology of propranolol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Haemodynamic effects of a new beta-blocking agent 'Sectral' (M & B 17803A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Haemodynamic effects of beta blockade in hypertrophic cardiomyopathy using Sectral (acebutolol; M and B 17803A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Haemodynamic effects of acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Haemodynamic effects of acute beta-adrenergic receptor blockade in congestive cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acute effects of acebutolol on cardiovascular function in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Cardiovascular effects of acebutolol and hydrochlorothiazide in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The effects of oral acebutolol and propranolol on forearm blood flow in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Effects of beta-adrenoceptor antagonists on central haemodynamics in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Quantitative assessment of bronchial beta-adrenoceptor blockade in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

21 January 2018

Beta-blockers and asthma

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Bronchial and cardiac beta-adrenoceptor blockade-a comparison of atenolol, acebutolol and labetalol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Comparison of the effects of acebutolol (Sectral) and practolol (Eraldin) on airways obstruction in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Adrenergic hypersensitivity after beta-blocker withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89,406 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Immediate central hemodynamic effects of five different beta-adrenoceptor-blocking agents, acebutolol, atenolol, pindolol, practolol, and propranolol, in patients with ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Comparison of the antilipolytic effect of metoprolol, acebutolol, and propranolol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The effect of acebutolol on tachycardia and performance during competition rifle shooting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Central effects of the beta-adrenergic blocking agent acebutolol. A quantitative EEG study using normalised slope descriptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Effects of the?-adrenoceptor antagonists acebutolol and metoprolol on sleep pattern in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The psychological side effects of acebutolol and atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Preliminary observations on the elimination of acebutolol in severe chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The effect of age on plasma levels of propranolol and practolol in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The effect of ageing on the hepatic clearance of propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Effects of age and cigarette smoking on propranolol disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Blood plasma binding of acebutolol and diacetolol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Pharmacokinetics of acebutolol after intravenous bolus administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The penetration of acebutolol and its major metabolite, diacetolol, into human cerebrospinal fluid and saliva [letter]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Lack of correlation between acetylator status and the production of the acetyl metabolite of acebutolol in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Observations on the pharmacokinetics of acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The influence of pH on the buccal absorption and plasma and renal elimination of acebutolol [letter]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acebutolol saliva excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acebutolol pharmacokinetics in renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acebutolol metabolite plasma concentration during chronic oral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

An open, multicentre study of acebutolol in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

An open, multicentre study of acebutolol, given as a single daily dose, in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Clinical Trial of Acebutolol (Sectral) in Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

A multicentre study of twice daily acebutolol (‘Sectral’) in the treatment of hypertension in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

A Multicentre Study of a Once Daily Dosage of Acebutolol* in the Treatment of Hypertension in General Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Controlled trial of acebutolol in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Comparison of once and twice daily administration of acebutolol in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acebutolol in essential hypertension: results of two multicenter studies against placebo and propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Comparison of acebutolol and hydrochlorothiazide in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Addition of acebutolol to diuretics in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Antihypertensive action of acebutolol (Sectral) when used concomitantly with hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

A randomized crossover comparison of acebutolol and methyldopa in the treatment of mild to moderate essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Antihypertensive beta blocking action as related to renin and age: A pharmacologic tool to identify pathogenetic mechanisms in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Reduced β-adrenoceptor sensitivity in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Trial of atenolol and chlorthalidone for hypertension in black South Africans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Suppression of premature ventricular contractions by acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Anti-arrhythmic properties of acebutolol (Bay c 7705), a new cardioselective beta-adrenergic blocking agent: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Approaches to sudden death from coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Differential antianginal responsiveness to acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acebutolol: Basis for the prediction of effect on exercise tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Evaluation of the beta-blocking drug acebutolol in angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischemia-induced left ventricular dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Treatment of premature ventricular complexes with acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Acebutolol in supraventricular arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Effective treatment of supraventricular arrhythmias with acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Antinuclear Antibodies and Cardiovascular Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Review of long-term treatment with labetalol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Development of antinuclear antibodies during acebutolol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Antinuclear antibodies in patients on acebutolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Beta-adrenoceptor blocker pharmacokinetics and the oral contraceptive pill

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

Mechanism of propranolol withdrawal phenomena

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03451.X

10.1002/J.1875-9114.1986.TB03451.X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference